

**COPY**

Application No. 10/643,404

2

Docket No.: 59753(48185)

Amendment dated December 22, 2006

Reply to Office Action dated September 26, 2006

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for prevention and/or therapy of arterial wall injury which is caused by coronary angioplasty or coronary-artery bypass graft (CABG), which comprises a step of administering 3-methyl-1-phenyl-2-pyrazolin-5-one or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans.
2. (Cancelled)
3. (Cancelled)
4. (Previously presented) The method according to claim 1 wherein the arterial wall injury is restenosis or neointimal formation after coronary angioplasty or coronary-artery bypass graft (CABG).
5. (Previously presented) The method according to claim 1 or 4 wherein the coronary angioplasty is percutaneous transluminal coronary angioplasty (PCTA) or percutaneous coronary intervention (PCI).